ClinicalTrials.gg
RecruitingNCT07165067Updated Dec 29, 2025

A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of AP601 in Solid Tumours, sponsored by AP Biosciences Inc.. Recruiting at 3 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by AP Biosciences Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

A Phase 1, Open-Label Study of the Safety, Tolerability,Pharmacokinetics, Pharmacodynamics and Clinical Activity of AP601 in Patients with Solid Tumours.The study is designed to find the highest dose of AP601 that can be given safely. Participants will be assigned to one of six cohorts. Each cohort will receive a different dose of the study medication, AP601, based on the body weight. Each cohort will initially enrol 1-3 participants. If no serious side effects are seen in the first participant(s), the next cohort will receive the next dose level.

Read the detailed description

Participants will receive a single infusion of AP601 once every 2 weeks (14 days) (Q2W) for up to 12 months.

Part 1 (Dose Escalation):

Part 1 is a dose escalation part, using an accelerated 3+3 design. Up to 6 dose levels are planned to be evaluated in Part 1.

Cohort 1 - 0.5mg/kg (1-6 participants) Cohort 2 - 1.25 mg/Kg (1-6 participants) Cohort 3 - 2.5 mg/Kg (3-6 participants) Cohort 4- 5.0 mg/Kg (3-6 participants) Cohort 5- 7.5 mg/Kg (3-6 participants) Cohort 6- 10.0 mg/Kg. (3-6 participants) At the first dose level, a single participant will be enrolled and observed for dose-limiting toxicities (DLTs) and adverse events (AEs) for 28 days (2 treatment cycles). If the participant does not experience any DLTs, then a new participant may be dosed at the next higher dose level and observed for the DLT period (28 days). There will be a maximum of 2 single-patient cohorts.

If in any of the single-patient cohorts a patient experiences a DLT, an additional 2 patients will be enrolled at that dose level and evaluated using 3+3 design rules.

Cohorts 3 and above will all use a standard 3+3 design, even if toxicity was not seen in the single-patient Cohorts 1 and 2.

Part 2 (Dose Expansion):

A dose expansion part may be initiated following completion of the dose escalation cohorts.

02

Conditions studied

  • Solid Tumours

Keywords

  • solid tumours
  • advanced or metastatic solid tumours
  • open label
03

In context

Lead sponsor

AP Biosciences Inc. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: 1. Patients with or cytologically proven locally unresectable advanced or solid tumors. Patients must be to at least one standard-of-care therapy, and/or have refused standard-of-care therapy.

2. performance status of 0 to 1 at Screening, with an estimated of at least 3 months.

3. Disease must have at least 1 assessable (long diameter ≥1 cm) lesion for evaluation of response by (RECIST) Version 1.1.

4. Patients with adequate organ and bone marrow function, in the absence of growth factors, including the specific laboratory findings of Absolute neutophil count, count, , , ALT, Serum total , Alkaline phosphatase, , INR or activated partial thromboplastin time, creatinine and albumin.

5. Female Volunteers must be of nonchild bearing potential i.e, surgically sterilised at least 6 weeks before Screening Visit or .

6. Females of must have a negative pregnancy test, agree not to attempt to become pregnant or donate Ova and agree to use from one month prior to Screening until at least 90 days after last dose of study drug, if not exclusively in a same-sex relationship or abstinent as a committed lifestyle.

Male Vonuteers:

  • Must agree not to donate sperm from signing the ICF until at aleast 90 days after the last dose of the study drug.
  • If engaging in sexual intercourse with a female partner who could become pregnant, must agree to use adequate contraception.
  • Willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.

Exclusion Criteria:

  1. Has received concurrent antitumor treatment or IPs within 28 days of C1D1. The antitumor treatments include chemotherapy, radiotherapy, immunotherapy, targeted therapy, hormonal therapy, or cytokine therapy.
  2. Has received prior CD73-targeted and/or CD137-targeted therapeutics.
  3. Has had major surgery within 28 days prior to C1D1 (excluding prior diagnostic ).
  4. Any unresolved toxicity (except alopecia) from prior therapy of ≥ Grade 1, prior to the day of the first dose of IP. Participants with Grade 2 toxicity that is not CS (e.g., alopecia, vitiligo), or that is deemed stable or irreversible (e.g., peripheral neuropathy) can be enrolled.
  5. History of any other , which has been active or treated within the past 2 years, with the exception of thyroid cancer, cervical intraepithelial neoplasia, basal cell carcinoma and squamous cell carcinoma.
  6. Prior history of an irAE with immunotherapy-related toxicities that resulted in discontinuation of prior immunotherapy.
  7. Current symptomatic or uncontrolled, untreated .
  8. Has received any organ transplantation including stem cell transplantation.
  9. Has received blood transfusions or growth factor support ≤ 14 days prior to screening.
  10. Has any significant acute or chronic infections including:

    1. Infection requiring systemic antibacterial, antifungal, or antiviral therapy within 14 days before first dose of AP601.
    2. Known active , or (HIV) infection.
  11. Current active, or history of, any disease that may relapse or immunodeficiencies.
  12. Any condition that required systemic treatment with either (> 10 mg daily of prednisone or equivalent) or other medication ≤ 14 days before first dose of AP601.
  13. Known severe reactions to monoclonal antibodies.
  14. Breastfeeding (or planning to breastfeed) at any time during the study, and for 90 days following study completion.
  15. Participants with a current or recent (within the past 12 months) diagnosis of alcohol or non-prescribed drug abuse, as defined by local guidelines.
  16. Evidence of cardiac dysfunction (defined as myocardial infarction within the last 6 months, Class II/III/IV heart failure, unstable angina, unstable cardiac arrhythmias, or known [LVEF] \<55%) or other CS cardiac pathology likely to impair the participants ability to participate in the study.
  17. Uncontrolled intercurrent illness including, but not limited to, uncontrolled hypertension, uncontrolled diabetes, uncontrolled endocrinopathy, severe active peptic ulcer disease or gastritis.
  18. Has received a live (or live attenuated) vaccination within 28 days of the first dose of AP601 and during the study period.
  19. Any other condition or prior therapy that in the opinion of the PI (or delegate) would make the volunteer unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Cohort 1: 0.5 mg/kg Participants will receive a single infusion of AP601 once every 2 weeks (14 days)

    Drug: AP601

  • Experimental
    Cohort 2

    Cohort 2: 1.25 mg/kg Participants will receive a single infusion of AP601 once every 2 weeks (14 days)

    Drug: AP601

  • Experimental
    Cohort 3

    Cohort 3: 2.5 mg/kg Participants will receive a single infusion of AP601 once every 2 weeks (14 days)

    Drug: AP601

  • Experimental
    Cohort 4

    Cohort 4: 5.0 mg/kg Participants will receive a single infusion of AP601 once every 2 weeks (14 days)

    Drug: AP601

  • Experimental
    Cohort 5

    Cohort 5: 7.5 mg/kg

    Drug: AP601

  • Experimental
    Cohort 6

    Cohort 6: 10.0 mg/kg

    Drug: AP601

Interventions

  • DrugAP601

    AP601 is a fully human bispecific antibody designed for the treatment of CD73-expressing solid tumours. Participants will receive a single infusion of AP601 once every 2 weeks (14 days) (Q2W) for up to 12 months. All doses of AP601 will be admistered intraveneously. The infusion time for all doses of AP601 in each patient will be approximately 60 to 120 minutes.

06

What researchers measure

Primary outcomes

  1. To determine the tolerability (MTD and/or maximum administered dose [MAD] of AP601 in patients with solid tumours.

    Estimate of the MTD based on DLTs observed during the DLT evaluation period.

    Time frame: Initial 28 days from the first dose of AP601 which is Cycle1Day1 (each cycle is 14 days) until Cycle2Day14 (each cycle is 14 days)

  2. To determine the tolerability of Recommend Phase 2 Dose [RP2D])- MTD and/or maximum administered dose [MAD] of AP601 in patients with solid tumours.

    RP2D is based on the safety data - Estimate of the MTD based on DLTs observed during the DLT evaluation period

    Time frame: TEAEs and SAEs will be assessed at Screening until 90-day safety follow up visit.

  3. To determine the tolerability of Recommend Phase 2 Dose [RP2D])

    RP2D tolerability is based on Pharmacokinetics data- blood samples will be collected to assess this.

    Time frame: Cycle 1 - pre-dose, immediately following End of Infusion (EOI), 4 hours, 24 hours, 72 hours, 168 hours. Cycle 2- pre-dose, EOI, 4 hours, 24hours, 72hours, 168hours, Cycle 3 to Cycle 24- Predose (each cycle is 14 days), 0-6 hours, End of Trial Visit.

  4. To determine the tolerability of Recommend Phase 2 Dose [RP2D])

    RP2D tolerability is based on Pharmacodynamics data- blood samples will be collected to assess this

    Time frame: PD will be assessed Cycle 1 - pre-dose, 24 hous, 72 hours, 168 hours. Cycle 2- pre-dose, 4 hours, 24hours, 72hours, 168hours, Cycle 3 to Cycle 24- Pre-dose (each cycle is 14days) and at End of Trial Visit.

  5. To determine the tolerability of Recommend Phase 2 Dose [RP2D]

    Recommend Phase 2 Dose \[RP2D\] is based on antitumor activity data.

    Time frame: Antitumour activity data will collected at End of Trial Visit , Safety Follow Up Visit (End of Trial + 30 days), Safety FUP Visit (End of Trial + 90 days) and at Survival Follow Up.

  6. To determine the tolerability of RP2D - Number of Participants with a Change from baseline in clinical laboratory parameters (haematology)

    Haematology - blood samples will be collected. All safety laboratory assessments will be assessed by a local laboratory according to their reference ranges.

    Time frame: Assessed at Screening, Cycle1 Day1 , Cycle2 Day1, Cycle 3 Day1 to Cycle 24 Day 1(each cycle is of 14 days), End of Trial Visit (EOT) and Safety Follow Up (EOT+ 30 days)

  7. To determine the tolerability of RP2D - Number of Participants with a Change from baseline in clinical laboratory parameters (clinical chemistry)

    Clinical Chemistry- blood samples will be collected. All safety laboratory assessments will be assessed by a local laboratory according to their reference ranges.

    Time frame: Assessed at Screening, Cycle1 Day1 , Cycle2 Day1, Cycle3 Day1 until Cycle 24 Day 1 (each cycle is of 14 days), End of Trial Visit and Safety FUP (EOT+ 30 days)

  8. To determine the tolerability of RP2D - Number of Participants with a Change from baseline in clinical laboratory parameters (Coagulation)

    Coagulation- blood samples will be collected. All safety laboratory assessments will be assessed by a local laboratory according to their reference ranges.

    Time frame: Assessed at Screening, Cycle1 Day1 , Cycle2 Day1, Cycle3 Day1 to last Cycle 24 Day 1(each cycle is of 14 days), End of Trial Visit and Safety FUP (EOT+ 30 days)

  9. To determine the tolerability of RP2D - Number of Participants with a Change from baseline in clinical laboratory parameters (Thyroid Function tests )

    Thyroid Function tests - blood samples will be collected. All safety laboratory assessments will be assessed by a local laboratory according to their reference ranges.

    Time frame: Assessed at Screening, Cycle1 Day1 , Cycle2 Day1, Cycle3 Day1 - until last Cycle 24 Day 1 (each cycle is of 14 days), End of Trial Visit and Safety FUP (EOT+ 30 days)

  10. To determine the tolerability of RP2D - Number of Participants with a Change from baseline in clinical laboratory parameters (urinalysis)

    Urine samples will be collected. All safety laboratory assessments will be assessed by a local laboratory according to their reference ranges.

    Time frame: Assessed at Screening, Cycle1 Day1 , Cycle2 Day1, Cycle3 Day1 - until last Cycle 24 Day 1 (each cycle is of 14 days), End of Trial Visit and Safety FUP (End of Trial Visit+ 30 days)

  11. To determine the tolerability of RP2D - Number of Participants with a Change from baseline in Vital signs measurements Pulse rate [PR], systolic and diastolic blood pressure [BP], temperature and respiratory rate [RR]

    Blood pressure will be measured using a sphygmomanometer, body temperature will be measured using a thermometer, Heart rate (HR) is measured using vital sign machine, respiratory rate is measured manually via 60-second count \[RR\]. All abnormal assessments measured as Clinically significant post dose will be recorded as AEs.

    Time frame: Assessed at Screening, Cycles 1 and 2 - Day 1, Day 2, Day 4, Day 8 Cycle 3 Day 1 - until last cycle 24 Day 1 (each cycle is 14 days), End of Trial Visit (EOT), Safety FUP (EOT + 30 days).

  12. To determine the tolerability of RP2D- Number of Participants with a Change from baseline in body weight

    Weight will be measured utilising scales.

    Time frame: Assessed at Screening, Cycles 1 and 2 - Day 1, Day 2, Day 4, Day 8 Cycle 3 Day 1 - until last cycle 24 Day 1(each cycle is 14 days), End of Trial Visit(EOT), Safety FUP (EOT + 30 days).

  13. To determine the tolerability of RP2D- Change from baseline in Eastern Cooperative Oncology Group (ECOG) score

    Graded using a 6 point scale

    Time frame: Assessed at Screening, Cycle1 Day1, Cycle2 Day1, Cycle3 Day1 up until last cycle 24 Day1 (each cycle is of 14 days), End of Trial Visit(EOT)and Safety FUP (EOT + 30 days) Visit.

  14. To determine the tolerability of RP2D- Change from baseline in measurements of HR in beats per minute

    12-lead ECG parameters include the measurements of HR in beats per minute. All ECGs will be performed in triplicate.

    Time frame: Assessed at Screening, Cycle1 Day1, Cycle2 Day1, Cycle3 Day1 until last cycle 24 Day 1(each cycle is of 14 days), End of Trial Visit(EOT) and Safety FUP (EOT + 30 days).

  15. To determine the tolerability of RP2D- Change from baseline in measurements of PR interval via 12-lead electrocardiogram

    12-lead ECG parameters include the measurements of PR interval. All ECGs will be performed in triplicate.

    Time frame: Assessed at Screening, Cycle1 Day1, Cycle2 Day1, Cycle3 Day1 until last cycle 24 Day 1(each cycle is of 14 days), End of Trial (EOT ) Visit and Safety FUP (EOT + 30 days).

  16. To determine the tolerability of RP2D- Change from baseline in measurements of QT interval via 12-lead electrocardiogram

    12-lead ECG parameters include measurements of QT duration. All ECGs will be in triplicate.

    Time frame: Assessed at Screening, Cycle1 Day1, Cycle2 Day1, Cycle3 Day1 until last cycle 24 Day 1(each cycle is of 14 days), End of Trial (EOT) Visit and Safety FUP (EOT + 30 days).

  17. To determine the tolerability of RP2D- Change from baseline in measurements of QRS duration via 12-lead electrocardiogram

    12-lead ECG parameters include the measurements of QRS duration. All 12-lead ECGs will be in triplicate.

    Time frame: Assessed at Screening, Cycle1 Day1, Cycle2 Day1, Cycle3 Day1 until last cycle 24 Day 1(each cycle is of 14 days), End of Trial (EOT) Visit and Safety FUP (EOT + 30 days).

Secondary outcomes

  1. To assess the PK of AP601 in patients with solid tumours - Serum PK concentration of AP601.

    Blood samples will be collected to assess PK.

    Time frame: Cycle 1 - Pre-dose, immediately following End of Infusion (EOI), 4 hours, 24 hours, 72 hours, 168 hours. Cycle 2- pre-dose, EOI, 4 hours, 24hours, 72hours, 168hours, Cycle 3 to Cycle 24 - Predose (each cycle is 14 days), 0-6 hours and End of Trial Visit.

  2. To assess the PK of AP601 in patients with solid tumours - Individual maximum concentration values, directly determined from the serum concentration time profiles for each participant (Cmax)

    Blood samples are collected to assess PK.

    Time frame: Cycle 1 - pre-dose, immediately following End of Infusion (EOI), 4 hours, 24 hours, 72 hours, 168 hours. Cycle 2- pre-dose, EOI, 4 hours, 24hours, 72hours, 168hours, Cycle 3 to Cyle 24- Predose(each cycle is 14 days), 0-6 hours and End of Trial Visit.

  3. To assess the PK of AP601 in patients with solid tumours -Serum clearance following IV administration (CL)

    Blood samples are collected to assess PK.

    Time frame: Cycle 1 - Pre-dose, immediately following End of Infusion (EOI), 4 hours, 24 hours, 72 hours, 168 hours. Cycle 2- pre-dose, EOI, 4 hours, 24hours, 72hours, 168hours, Cycle 3 -to Cycle 24- Predose(each cycle is 14days), 0-6 hours and End of Trial Visit.

  4. To assess the PK of AP601 in patients with solid tumours -Area under the serum concentration-time curve (AUC) from time zero to 168 hours post-dose (AUC0-168)

    Blood samples are collected to assess PK.

    Time frame: Cycle 1 - Pre-dose, immediately following End of Infusion (EOI), 4 hours, 24 hours, 72 hours, 168 hours. Cycle 2- pre-dose, EOI, 4 hours, 24hours, 72hours, 168hours, Cycle 3 to Cycle 24 Predose(each cycle is 14days), 0-6 hours and End of Trial Visit.

  5. To assess the PK of AP601 in patients with solid tumours - AUC from time zero to the last time point with measurable concentration using the linear trapezoidal rule (AUClast)

    Blood samples are collected to assess PK.

    Time frame: Cycle 1 - Pre-dose, immediately following End of Infusion (EOI), 4 hours, 24hours, 72 hours, 168 hours. Cycle 2- pre-dose, EOI, 4 hours, 24hours, 72hours, 168hours, Cycle 3 to Cycle 24- Predose(each cycle is 14days), 0-6 hours and End of Trial Visit.

  6. To assess the PK of AP601 in patients with solid tumours - The time to attain maximum concentration (Tmax)

    Blood samples are collected to assess PK.

    Time frame: Cycle 1 - pre-dose, immediately following End of Infusion (EOI), 4 hours, 24 hours, 72 hours, 168 hours. Cycle 2- pre-dose, EOI, 4 hours, 24hours, 72hours, 168hours, Cycle 3 to Cycle 24- Predose (each cycle is 14days), 0-6 hours and End of Trial Visit.

  7. To assess the PK of AP601 in patients with solid tumours - Terminal elimination half-life (T1/2)

    Blood samples are collected to assess PK.

    Time frame: Cycle 1 - Pre-dose, immediately following End of Infusion (EOI), 4 hours, 24 hours, 72 hours, 168 hours. Cycle 2- pre-dose, EOI, 4 hours, 24hours, 72hours, 168hours, Cycle 3 to Cycle 24- Predose(each cycle is 14days), 0-6 hours and End of Trial Visit.

  8. To assess the PK of AP601 in patients with solid tumours - Volume of distribution (Vz)

    Blood samples are collected to assess PK.

    Time frame: Cycle 1 - pre-dose, immediately following End of Infusion (EOI), 4 hours, 24 hours, 72 hours, 168 hours. Cycle 2- pre-dose, EOI, 4 hours, 24hours, 72hours, 168hours, Cycle 3 to Cycle 24- Predose(each cycle is 14days), 0-6 hours and End of Trial Visit.

  9. To assess the PK of AP601 in patients with solid tumours - Trough concentration (Ctrough)

    Blood samples are collected to assess PK.

    Time frame: Cycle 1 - pre-dose, immediately following End of Infusion (EOI), 4 hours, 24 hours, 72 hrs, 168 hours. Cycle 2- pre-dose, EOI, 4 hours, 24hours, 72hours, 168hours, Cycle 3 to Cycle 24- Predose(each cycle is 14days), 0-6 hours and End of Trial Visit.

  10. To assess the Immunogenicity of AP601 in patients with solid tumours.

    Immunogenicity parameters will be assessed through analysis of the number and percentage of patients who develop anti-drug antibodies (ADA).

    Time frame: Assessed at Cycle1 Day1 - Pre-dose, Cycle2 Day1 - Predose, Cycle3 Day1- Predose until Last Cycle 24 Day 1 (each cycle is of 14 days) and End of Trial Visit.

  11. To assess the antitumor activity of AP601 in patients with solid tumours.

    This data will be collected through a follow up phone call following the last dose of AP601, through to last contact with the participant.

    Time frame: Antitumour activity data will collected at End of Trial(EOT) Visit , Safety FUP Visit (EOT + 30 days), Safety Follow Up Visit (EOT + 90 days) and at Survival Follow Up.

  12. To evaluate the preliminary efficacy of AP601 in patients with solid tumours- Objective Response Rate (ORR)

    Preliminary efficacy will be assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

    Time frame: Upto 2 years

  13. To evaluate the preliminary efficacy of AP601 in patients with solid tumours- Disease Control Rate (DCR)

    Preliminary efficacy will be assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

    Time frame: Upto 2 years

  14. To evaluate the preliminary efficacy of AP601 in patients with solid tumours- Clinical Benefit Response (CBR)

    Preliminary efficacy will be assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

    Time frame: Upto 2 years

07

Study locations

1 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Our IPD sharing plan is not yet developed. We will consider data sharing at a later date.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Dec 2027, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2025
First posted
Sep 10, 2025
StartEst.
Jan 21, 2026
Primary completionEst.
Dec 27, 2027
CompletionEst.
Jan 30, 2028
Last update
Dec 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07165067
Lead sponsor
AP Biosciences Inc.
Collaborators
Avance Clinical Pty Ltd.
Responsible party
Sponsor
First posted
Sep 10, 2025
Start date
Jan 21, 2026 (estimated)
Primary completion
Dec 27, 2027 (estimated)
Completion
Jan 30, 2028 (estimated)
Last update
Dec 29, 2025

Study contacts

Grace Lu
Contact
cwlu@apbioinc.com
886-2-2653-2886 ext. 710

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion